Life-threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers

Michael E. Mullins, B (Zane) Horowitz, Dennis H J Linden, Gregory W. Smith, Robert Norton, Jack Stump

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Mibefradil is a T-type and L-type calcium channel blocker (CCB) released in the United States in 1997 for management of hypertension and chronic stable angina. Postmarketing surveillance revealed a potential serious interaction between mibefradil and β-blockers, digoxin, verapamil, and diltiazem, especially in elderly patients. The manufacturer voluntarily withdrew mibefradil on June 8, 1998. We describe 4 cases of cardiogenic shock in patients taking mibefradil and β-blockers who began taking dihydropyridine CCBs. One case resulted in death; the other 3 survived episodes of cardiogenic shock with intensive support of heart rate and blood pressure. Physicians who are preparing to switch patients' medications from mibefradil to other antihypertensive agents should be aware of these potentially life-threatening drug-drug interactions.

Original languageEnglish (US)
Pages (from-to)157-158
Number of pages2
JournalJournal of the American Medical Association
Volume280
Issue number2
DOIs
StatePublished - Jul 8 1998

Fingerprint

Mibefradil
Calcium Channel Blockers
Cardiogenic Shock
L-Type Calcium Channels
Stable Angina
Diltiazem
Digoxin
Verapamil
Drug Interactions
Antihypertensive Agents
Heart Rate
1,4-dihydropyridine
Blood Pressure
Hypertension
Physicians
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Life-threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers. / Mullins, Michael E.; Horowitz, B (Zane); Linden, Dennis H J; Smith, Gregory W.; Norton, Robert; Stump, Jack.

In: Journal of the American Medical Association, Vol. 280, No. 2, 08.07.1998, p. 157-158.

Research output: Contribution to journalArticle

Mullins, Michael E. ; Horowitz, B (Zane) ; Linden, Dennis H J ; Smith, Gregory W. ; Norton, Robert ; Stump, Jack. / Life-threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers. In: Journal of the American Medical Association. 1998 ; Vol. 280, No. 2. pp. 157-158.
@article{0f63df213045418b91333e66b669be00,
title = "Life-threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers",
abstract = "Mibefradil is a T-type and L-type calcium channel blocker (CCB) released in the United States in 1997 for management of hypertension and chronic stable angina. Postmarketing surveillance revealed a potential serious interaction between mibefradil and β-blockers, digoxin, verapamil, and diltiazem, especially in elderly patients. The manufacturer voluntarily withdrew mibefradil on June 8, 1998. We describe 4 cases of cardiogenic shock in patients taking mibefradil and β-blockers who began taking dihydropyridine CCBs. One case resulted in death; the other 3 survived episodes of cardiogenic shock with intensive support of heart rate and blood pressure. Physicians who are preparing to switch patients' medications from mibefradil to other antihypertensive agents should be aware of these potentially life-threatening drug-drug interactions.",
author = "Mullins, {Michael E.} and Horowitz, {B (Zane)} and Linden, {Dennis H J} and Smith, {Gregory W.} and Robert Norton and Jack Stump",
year = "1998",
month = "7",
day = "8",
doi = "10.1001/jama.280.2.157",
language = "English (US)",
volume = "280",
pages = "157--158",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Life-threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers

AU - Mullins, Michael E.

AU - Horowitz, B (Zane)

AU - Linden, Dennis H J

AU - Smith, Gregory W.

AU - Norton, Robert

AU - Stump, Jack

PY - 1998/7/8

Y1 - 1998/7/8

N2 - Mibefradil is a T-type and L-type calcium channel blocker (CCB) released in the United States in 1997 for management of hypertension and chronic stable angina. Postmarketing surveillance revealed a potential serious interaction between mibefradil and β-blockers, digoxin, verapamil, and diltiazem, especially in elderly patients. The manufacturer voluntarily withdrew mibefradil on June 8, 1998. We describe 4 cases of cardiogenic shock in patients taking mibefradil and β-blockers who began taking dihydropyridine CCBs. One case resulted in death; the other 3 survived episodes of cardiogenic shock with intensive support of heart rate and blood pressure. Physicians who are preparing to switch patients' medications from mibefradil to other antihypertensive agents should be aware of these potentially life-threatening drug-drug interactions.

AB - Mibefradil is a T-type and L-type calcium channel blocker (CCB) released in the United States in 1997 for management of hypertension and chronic stable angina. Postmarketing surveillance revealed a potential serious interaction between mibefradil and β-blockers, digoxin, verapamil, and diltiazem, especially in elderly patients. The manufacturer voluntarily withdrew mibefradil on June 8, 1998. We describe 4 cases of cardiogenic shock in patients taking mibefradil and β-blockers who began taking dihydropyridine CCBs. One case resulted in death; the other 3 survived episodes of cardiogenic shock with intensive support of heart rate and blood pressure. Physicians who are preparing to switch patients' medications from mibefradil to other antihypertensive agents should be aware of these potentially life-threatening drug-drug interactions.

UR - http://www.scopus.com/inward/record.url?scp=0032496879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032496879&partnerID=8YFLogxK

U2 - 10.1001/jama.280.2.157

DO - 10.1001/jama.280.2.157

M3 - Article

C2 - 9669789

AN - SCOPUS:0032496879

VL - 280

SP - 157

EP - 158

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 2

ER -